Editorial
doi: 10.1016/j.jval.2024.01.006.
Epub 2024 Jan 27.
Drug Pricing, Patient Welfare, and Cost-Effectiveness Analysis
Affiliations
- PMID: 38286248
- DOI: 10.1016/j.jval.2024.01.006
Item in Clipboard
Editorial
Drug Pricing, Patient Welfare, and Cost-Effectiveness Analysis
Value Health.
2024 Mar.
Free article
No abstract available
Conflict of interest statement
Author Disclosures The authors reported no conflicts of interest.
Similar articles
-
The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.Value Health. 2023 Jan;26(1):91-98. doi: 10.1016/j.jval.2022.06.007. Epub 2022 Aug 4. Value Health. 2023. PMID: 35933271
-
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.BioDrugs. 2023 May;37(3):421-432. doi: 10.1007/s40259-023-00586-6. Epub 2023 Feb 25. BioDrugs. 2023. PMID: 36840914
-
The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets.J Health Econ. 2023 Jul;90:102778. doi: 10.1016/j.jhealeco.2023.102778. Epub 2023 Jun 5. J Health Econ. 2023. PMID: 37343309
-
[Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].Rev Med Chil. 2014 Jan;142 Suppl 1:S33-8. doi: 10.4067/S0034-98872014001300006. Rev Med Chil. 2014. PMID: 24861178 Review. Spanish.
-
[Risk sharing methods in middle income countries].Acta Pharm Hung. 2012;82(1):43-52. Acta Pharm Hung. 2012. PMID: 22570986 Review. Hungarian.
Cited by
-
Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis.Front Immunol. 2025 Jul 1;16:1591517. doi: 10.3389/fimmu.2025.1591517. eCollection 2025. Front Immunol. 2025. PMID: 40666510 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
